Multifocality and recurrence of urothelial carcinoma may result from either the ®eld eect of carcinogens leading to oligoclonal tumors or monoclonal tumor spread. Previous molecular studies, favoring the monoclonality hypothesis, are mostly limited to the urinary bladder. We investigated genetic alterations in a total of 94 synchronous or metachronous multifocal tumors from 19 patients with at least one tumor both in the upper and lower urinary tract. Loss of heterozygosity (LOH) was determined using eight markers on chromosome 9 and one marker on 17p13 (p53). Microsatellite instability was investigated at six loci and protein expression of MSH2 and MLH1 was evaluated by immunohistochemistry. In addition, exons 5 ± 9 of the p53 gene were sequenced. Deletions at chromosome 9 were found in 73% of tumors and at 17p13 in 18% of tumors. There was no signi®cant dierence in the frequency of LOH in the upper and lower urinary tract. Deletions at 9p21 were signi®cantly correlated with invasive tumor growth. The pattern of deletion revealed monoclonality of all tumors in nine patients. In ®ve patients there were at least two tumor clones with dierent genetic alterations. In four of these patients the dierent clones occured in the bladder and subsequently in the ureter and renal pelvis. All four patients with p53 mutations revealed identical mutations in all tumors. Thus, multifocal urothelial carcinomas are frequently monoclonal, whereas others show oligoclonality, providing molecular evidence for ®eld cancerization. Intraluminal tumor cell seeding appears to be an important mechanism of multifocal occurence and recurrence of urothelial carcinomas. Oncogene (2001) 20, 4910 ± 4915.
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Keywords: urothelial carcinoma; upper and lower urinary tract; LOH; oligoclonality; p53 mutation Synchronous or metachronous multifocal occurrence is a characteristic feature of urothelial carcinoma (Bender and Jones, 1998) , but the clonal origin of these multiple tumors remains elusive. One hypothesis proposes that all tumors arise from a single transformed cell and are therefore monoclonal (Sidransky et al., 1992) , spreading by either intraepithelial migration or intraluminal seeding (Harris and Neal, 1992) . The other hypothesis proposes a ®eld eect of urothelial carcinogens that results in the independent malignant transformation of spatially distinct urothelial cells (Heney et al., 1978) . Field cancerization is also presumed to be the cause for multifocal tumor development in the oral cavity and upper aerodigestive tract, although there is molecular evidence for a widespread expansion of a single malignant clone populating extensive areas of the mucosa (Franklin et al., 1997; Partridge et al., 1997) . The clonality of urothelial carcinomas is receiving more and more clinical attention, as detection of genetic alterations in urine samples is increasingly utilized for both diagnosis and follow-up of patients with urothelial cancer (Steiner et al., 1997) .
Most molecular studies favor the monoclonal origin of urothelial carcinoma with intraepithelial spread or intraluminal seeding (Sidransky et al., 1992; Bender and Jones, 1998; Takahashi et al., 1998; Simon et al, 2001) . Some studies, however, provide evidence for the existence of more than one tumor clone, particularly in early stage bladder carcinoma (Paiss et al., 1997; Hartmann et al., 2000) . Studies investigating the clonality of urothelial carcinoma are mostly limited to the urinary bladder. Only one recent study investigated simultaneous or consecutive urothelial carcinomas of the bladder and the upper urinary tract, ®nding a higher frequency of multiple tumor clones (Takahashi et al., 2001) .
The aim of this study was to investigate genetic alterations and clonality of combined synchronous or metachronous multifocal tumors of the upper and lower urinary tract in a large number of patients. Overgrowth of one tumor clone by another tumor as well as tumor expansion by intraepithelial migration are unlikely when examining the clonality of upper and lower urinary tract carcinomas because of the large spatial distance of the multiple tumors.
Tumor tissue was carefully microdissected from paran-embedded tissue to obtain samples containing at least 80% tumor cells (Dietmaier et al., 1999) . Loss of heterozygosity (LOH) analysis at chromosome 9, a genetic alteration generally accepted as an early event in urothelial carcinogenesis (Simoneau et al., 1999) , was used as a marker for clonality, since a strong correlation between LOH analysis of chromosome 9q and X-chromosome inactivation analysis has been reported (Sidransky et al., 1992) . The great advantage of LOH analysis is the applicability to male patients who make up the majority of patients with urothelial carcinoma. For each arm of chromosome 9, four polymorphic microsatellite markers (Figure 1 ) were used and one marker was tested for the p53 tumor suppressor gene locus at 17p13. Exons 5 ± 9 of the p53 gene were directly sequenced, and microsatellite instability (MSI) was analysed at six loci using the extended NIH consensus primer panel for colorectal cancer (see Table 1 ; Boland et al., 1998) as well as immunohistochemical staining for the mismatch repair proteins hMLH1 and hMSH2.
Overall, 19 patients with 94 synchronous or metachronous multifocal urothelial carcinomas were studied. Every patient had at least one tumor in the upper (renal pelvis, ureter) and one tumor in the lower (bladder, urethra) urinary tract. The average number of tumors per patient was 4.9, and tumor stage was distributed as follows: 39 (42%) pTa, 33 (35%) pT1, 21 (22%) pT2 ± 4 and 1 (1%) CIS. The study included multifocal upper urinary tract tumors in nine of 19 patients, upper urinary tract tumors with subsequent bladder tumors (n=10), simultaneous multifocal tumors (n=2), and also tumors of the ureter and renal pelvis developing after the ®rst bladder cancer (n=7).
Deletions at chromosome 9 and at the p53 locus on chromosome 17p13 were detected in 69 (73%) tumors and 15 (18%) tumors, respectively. Forty-three (46%) tumors revealed LOH at 9p and 55 (59%) tumors had a deletion at 9q. Deletions at both 9p and 9q occured in 29 (31%) tumors. Deletion at 9p alone were observed in 14 (15%) tumors and isolated 9q deletions occurred in 26 (28%) tumors. Interestingly, 13 of 14 (93%) tumors with an isolated 9p deletion were invasive (5pT1), compared to only 12 of 26 (46%) tumors with an isolated 9q alteration (P50.01). The correlation of invasiveness and 9p deletion was independent of simultaneous deletions of the p53 gene which has been shown to be associated with urothelial tumor invasion (Bender and Jones, 1998) . There were no signi®cant dierences in the rate of genetic alterations at chromosome 9 of tumors of the upper and lower urinary tract, although upper urinary tract tumors showed a deletion frequency 14% lower at 9p and 7% lower at 9q, respectively.
Five patients with a total of 18 tumors showed neither chromosome 9 nor chromosome 17p13 deletions. The deletion pattern of nine patients was compatible with a monoclonal origin of their tumors from a single progenitor cell. Three of these nine patients harboured identical deletions at all investigated chromosomal regions, whereas six patients had carcinomas that exhibited one common deletion as well as diverse alterations at other loci, compatible with development of subclones.
Monoclonality was con®rmed by sequencing the p53 tumor suppressor gene. Exons 5 ± 9 were directly sequenced in one upper and one lower urinary tract tumor from each patient. In patients showing either LOH at 17p13 or a p53 mutation, sequencing of the p53 gene was performed in all tumors. Only four (21%) patients with a total of 26 tumors had a p53 mutation. All patients with a p53 mutation showed the identical mutation (Figure 2 ) in all tumors and revealed corresponding monoclonal results in the LOH analysis. Of 27 tumors with a p53 deletion and/or a p53 mutation in exons 5 ± 9, only 11 (41%) carried both a deletion and a mutation.
Five (26%) patients showed evidence of oligoclonality with at least two dierent tumor clones (Table 1) . In four of these ®ve patients the dierent clones were identi®ed in the upper and lower urinary tract. In all four patients the bladder tumor developed before the upper urinary tract tumor. Two patients (09, 18) showed deletions of dierent alleles at chromosome 9q. Because chromosome 9 deletions are the earliest Figure 1 Localization of the markers on chromosome 9. Tumor tissue and normal tissue (renal parenchyma) were microdissected from methylen-blue stained sections with a needle under an inverted microscope to obtain at least 80% tumor cells. After proteinase K digestion overnight, DNA was isolated using the Quiagen tissue kit (Quiagen, Germany). LOH analysis was performed as described previously (Hartmann et al., 2000) . All LOH were con®rmed in a second independent PCR reaction. Primer sequences and PCR conditions can be obtained from the authors or at http://www.uni-regensburg.de/Fakultaeten/Medizin/ Pathologie/Publikationen/Hafner.html genetic alteration in bladder cancer identi®ed so far (Simoneau et al., 1999) , this strongly indicates two dierent tumor cell clones in these patients. One patient (02) developed a bladder carcinoma with no detectable genetic alterations and an ureteral carcinoma with deletions, as well as microsatellite instability (MSI) at two loci on chromosome 9 and MSI at four of six investigated NIH consensus marker loci and negative immunohistochemical staining for the mismatch repair protein hMSH2. In patient 12, the tumor in the ureter also showed MSI and loss of hMSH2 expression, whereas the bladder tumor revealed no genetic alterations. In patient 07, LOH at all investigated chromosomal regions (9p, 9q, 17p) in the bladder cancer and the absence of these changes in the in®ltrating ureter tumor supports the development of a second tumor clone. Although it is theoretically possible that the tumors with additional LOH or MSI in patients 02, 07 and 12 are subclones from the tumors without these changes and therefore tumor progression related, we think that the data strongly suggest the existence of dierent tumor clones (Table 1 ; Figure 3a , b).
In ®ve (26%) patients the clonal origin of their tumors could not be studied, because these patients had tumors that lacked alterations at the investigated loci.
In summary, the clonal origin of tumors from 14 patients could be determined, with nine (64%) having monoclonal tumors and ®ve (36%) possessing at least two dierent tumor clones. Unfortunately, four of the ®ve patients with oligoclonal tumors were male and the ®fth patient was not informative for a polymorphic marker within the human androgene receptor gene (Sidransky et al., 1992) , hindering from the use of the HUMARA assay for detection of the X-chromosomal inactivation pattern in this study. 
Data for ®ve patients with oligoclonal tumors. Number of patient and diagnosis time in months after the primary tumor diagnosis (the entire data set for all 19 patients can be obtained at http://www.uni-regensburg.de/Fakultaeten/Medizin/Pathologie/Publikationen/Hafner.html). 2: According to the UICC TNM classi®cation (Hermanek et al., 1998) . 3: Location of the tumor (N=normal tissue, B=bladder, P=renal pelvis, U=ureter). 4: Number of specimen. 5: LOH data for nine microsatellite markers on chromosome 9 and 17p13 (for marker localization see Figure 1 ): &&=retention of heterozygosity, &&=deletion of the shorter allele, &&=deletion of the longer allele, &&=homozygous deletion, MSI=microsatellite instability, NI=not informative, NA=not available. 6: Number of microsatellite instable loci using the extended NIH consensus marker set for MSI detection on colorectal cancer (BAT25, BAT26, BAT40, D2S123, APC, D17S250; (Boland et al., 1998) . High grade microsatellite instability of a tumor requires at least two instable loci. Both tumor 3 of patient 02 and tumor 2 of patient 12 showed loss of expression of hMSH2. The other tumors of the two patients revealed normal expression of hMSH2 and hMLH1. MSI analysis and immunohistochemical staining for hMSH2 and hMLH1 mismatch repair proteins were done as described previously (Dietmaier et al., 1997) .
Little is known about genetic alterations in upper urinary tract tumors. Our results show that there is no signi®cant dierence in the frequency of chromosome 9 alterations between upper and lower tract tumors. Chromosome 9 alterations are widely accepted as one of the earliest and most common events in urothelial carcinogenesis (Bender and Jones, 1998) . In accordance with Takahashi et al. (2001) , we believe that there are biologically and also clinically important dierences between the urothelium of the upper and lower urinary tract, which may be just due to dierent degrees of exposure to carcinogens. In Balkan endemic nephropathy the risk of upper urinary tract, but not bladder cancers is increased (Radovanovic et al., 1985) . The recent clinical insights in HNPCC-related tumor entities seems to group upper urinary tract tumors in the category of HNPCC-related tumors (Aarnio et al., 1995; Arzimanoglou et al., 1998) , while lower urinary tract tumors show no relation to genetic tumor patterns, thus highlighting biological dissimilarities in dierent urothelial sites. Our experimental ®ndings of frequent microsatellite instability in tumors of the ureter and renal pelvis, but not in tumors of the urinary bladder (unpublished results) support this view. Takahashi et al. (2001) , too, found dierent patterns of microsatellite alterations and a higher degree of genetic instability in patients with multifocal urothelial carcinomas and involvement of the upper urinary tract.
There was a signi®cant correlation between 9p deletions and invasive urothelial carcinoma, whereas isolated 9q deletions were more often observed in noninvasive tumors. This is an interesting ®nding worth studying further prospectively, since it could potentially indicate a marker for predicting the clinical behavior of papillary urothelial tumors. Our ®ndings indicate an important role of 9q deletions in the initial development of papillary urothelial tumors, as reported by Simoneau et al. (1999) . In contrast, other investigators have identi®ed 9p alterations in non-invasive papillary tumors (Orlow et al., 1995; Hartmann et al., 2000) .
Clonality studies in multifocal urothelial cancers will help to understand the biology of urothelial tumors, with potential clinical relevance. Detection of microsatellite alterations or p53 mutations in urine samples as genetic ®ngerprints of a tumor clone could be used for both screening and follow-up of cancer patients (Sidransky et al., 1991; Steiner et al., 1997) . Genetic divergence of dierent clones could potentially lead to false negative results. In our study nine of 14 (64%) informative patients revealed tumors with a monoclonal origin, consistent with Takahashi et al. (1998) , who found monoclonal tumors in 20 of 25 patients. Li and Cannizzaro (1999) demonstrated a monoclonal Figure 2 Sequencing results of the tumors in four patients with mutations in the p53 gene. Exons 5 ± 9 were ampli®ed separately utilizing a nested PCR approach. After precipitation with polyethylenglycol, 1 ± 4 mg of the PCR product was directly sequenced on an ABI 373. Primer sequences and PCR conditions can be obtained from the authors or at http://www.uni-regensburg.de/ Fakultaeten/Medizin/Pathologie/Publikationen/Hafner.html origin of 35 low-grade pTa tumors from 10 patients by determining the X-chromosome inactivation pattern. Other investigators report similar molecular evidence for a monoclonal origin of multiple urothelial carcinomas (Sidransky et al., 1992; Habuchi et al., 1993 ).
Herein we demonstrate the existence of more than one tumor cell clone in ®ve patients with combined upper and lower urinary tract tumors, supporting the hypothesis of ®eld eect cancerization of the urothelium by exogenous carcinogens. Yamamoto et al. (1998) used the experimental bladder carcinogen Nbutyl-N-(4-hydroxybutyl)nitrosamine in chimeric C3H/ HeN ± BALB/c mice and observed multiple tumors of dierent parental origin in 30% of the mice, suggesting polyclonal tumor development. Paiss et al. (1997) found oligoclonality in 36% of pTa bladder tumors and Hartmann et al. (2000) found oligoclonality in 10% of patients with multifocal early stage bladder tumors (pTa, G1). In contrast, none of the 35 pTa grade 1 and 2 tumors in the study of Li and Cannizzaro (1999) showed oligoclonality. Spruck et al. (1994) reported the existence of dierent clones in three patients with CIS and simultaneous bladder tumors. It is possible that oligoclonality is more common in early lesions, and that tumor progression to invasive and/or poorly dierentiated stages leads to monoclonality by overgrowth of one clone. The only other study investigating multifocal tumors in the upper and lower urinary tract provided also molecular evidence for the existence of dierent tumor clones within one patient (Takahashi et al., 2001) . However, both patients with multifocal upper urinary tract tumors and patients with upper urinary tract tumors developing after the ®rst bladder cancer were not studied. Interestingly, four of ®ve patients with dierent tumor clones in our study developed tumors in the renal pelvis or ureter after the initial bladder cancer (see Table 1 ).
We identi®ed a group of four patients with identical p53 gene mutations in the tumors of the upper and lower urinary tract. Habuchi et al. (1993) also reported identical p53 mutations in four patients with metachronous tumors of the renal pelvis/ureter and bladder. Waridel et al. (1997) found identical p53 mutations in the normal epithelium of patients with multifocal tumors of the upper aero-digestive tract in 76% of cases, providing evidence for expansion and spread of a p53-mutant tumor clone. The ®nding of identical mutations in upper and lower urinary tract tumors suggests that the p53 mutation occurred before tumor spread. The distance between such tumors of the renal pelvis and bladder indicates that clonal expansion occurs by intraluminal seeding of malignant urothelial cells rather than by intraepithelial migration (Harris and Neal, 1992; Habuchi et al., 1993; Xu et al., 1996; Li and Cannizzaro, 1999) .
In conclusion, there were no signi®cant dierences in the frequency of deletions on chromosome 9 in tumors of the upper and lower urinary tract. Our results provide evidence for possible oligoclonality in a subset of urothelial carcinomas. Multifocal occurrence and recurrence of urothelial cancers appear to be the result of both monoclonal tumor spread by intraluminal seeding and, less frequently, the development of distinct tumor clones as a result of ®eld eect carcinogenesis. Table 1) 
